DC-CIK免疫治疗联合化疗治疗血液恶性肿瘤的安全性和有效性分析

Safety and Efficacy Analysis of DC-CIK Immunotherapy Combined with Chemotherapy for Hematological Malignancies

本研究旨在研究树突状细胞-细胞因子诱导的杀伤细胞(dendritic cell and cytokine-induced killer cell,DC-CIK)免疫治疗联合化疗治疗血液恶性肿瘤的临床疗效。本研究从PubMed、Web of Science、The Cochrane Library、Embase、CNKI、WanFang Data、SinoMed和VIP等数据库中,收集2000年1月至2023年2月发表的符合要求的随机对照研究,应用RevMan 5.4.1软件进行Meta分析。共纳入15篇文献,894例患者,包括686例骨髓瘤患者和208例白血病患者,其中DC-CIK免疫治疗联合化疗治疗组共451例,设置为联合治疗组,而单纯化疗组共443例,设置为化疗(对照)组。分析结果显示,联合治疗组在临床疗效、预后情况、生活质量及各项免疫指标(T淋巴细胞亚群分布和细胞因子分泌水平)等方面均优于化疗组,且不会给患者带来特异性的副作用。研究结果表明,DC-CIK免疫治疗联合化疗能够改善恶性血液肿瘤患者的免疫功能,增强机体的抗肿瘤能力,从而显著提高临床治疗的效果。

The aim of this study is to investigate the clinical efficacy of dendritic cell and cytokine-induced killer cell(DC-CIK)immunotherapy in combination with chemotherapy in the treatment of hematological malignancies.This study collected eligible randomized controlled studies published from January 2000 to February 2023 from databases such as PubMed,Web of Science,The Cochrane Library,Embase,CNKI,WanFang Data,SinoMed and VIP database respectively by the same method,and applied RevMan 5.4.1 software for Meta-analysis.A total of 15 papers related to 894 patients,wherein 686 myeloma patients and 208 leukemia patients.There were 451 patients in the DC-CIK combined with chemotherapy treatment group were set as combination therapy group,while a total of 443 patients in the chemotherapy treatment group were set as the chemotherapy(control)group.The analysis results showed that the combination treatment group was better than the chemotherapy group in terms of clinical efficacy,prognosis,survival quality and various immune indexes(T lymphocyte subpopulation distribution and cytokine secretion level),and did not cause specific side effects to patients.This study demonstrates that DC-CIK immunotherapy combined with chemotherapy can significantly improve the clinical efficacy of patients with malignant hematological tumors,improve their immune function and enhance the anti-tumor ability of the body.